AU2022272659A1 - Novel protein and nucleic acid sequences for covid-19 vaccines - Google Patents

Novel protein and nucleic acid sequences for covid-19 vaccines Download PDF

Info

Publication number
AU2022272659A1
AU2022272659A1 AU2022272659A AU2022272659A AU2022272659A1 AU 2022272659 A1 AU2022272659 A1 AU 2022272659A1 AU 2022272659 A AU2022272659 A AU 2022272659A AU 2022272659 A AU2022272659 A AU 2022272659A AU 2022272659 A1 AU2022272659 A1 AU 2022272659A1
Authority
AU
Australia
Prior art keywords
seq
aminoacid
cov
sars
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022272659A
Other languages
English (en)
Other versions
AU2022272659A9 (en
Inventor
Marcello Allegretti
Andrea Rosario Beccari
Franca Cattani
Annamaria Cimini
Elisabetta Maria Ester MAURI
Carmine TALARICO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of AU2022272659A1 publication Critical patent/AU2022272659A1/en
Publication of AU2022272659A9 publication Critical patent/AU2022272659A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022272659A 2021-05-14 2022-05-16 Novel protein and nucleic acid sequences for covid-19 vaccines Pending AU2022272659A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21173941.2A EP4088738A1 (en) 2021-05-14 2021-05-14 Novel protein and nucleic acid sequences for covid-19 vaccines
EP21173941.2 2021-05-14
PCT/EP2022/063214 WO2022238585A1 (en) 2021-05-14 2022-05-16 Novel protein and nucleic acid sequences for covid-19 vaccines

Publications (2)

Publication Number Publication Date
AU2022272659A1 true AU2022272659A1 (en) 2023-11-23
AU2022272659A9 AU2022272659A9 (en) 2023-11-30

Family

ID=75936784

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022272659A Pending AU2022272659A1 (en) 2021-05-14 2022-05-16 Novel protein and nucleic acid sequences for covid-19 vaccines

Country Status (10)

Country Link
US (1) US20250282831A1 (cg-RX-API-DMAC7.html)
EP (2) EP4088738A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024517345A (cg-RX-API-DMAC7.html)
CN (1) CN117915945A (cg-RX-API-DMAC7.html)
AU (1) AU2022272659A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023023794A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219586A1 (cg-RX-API-DMAC7.html)
IL (1) IL308407A (cg-RX-API-DMAC7.html)
WO (1) WO2022238585A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202311432B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024245344A1 (zh) * 2023-05-30 2024-12-05 石药集团巨石生物制药有限公司 预防新型冠状病毒奥密克戎突变株的mRNA疫苗

Also Published As

Publication number Publication date
EP4088738A1 (en) 2022-11-16
CN117915945A (zh) 2024-04-19
CA3219586A1 (en) 2022-11-17
JP2024517345A (ja) 2024-04-19
WO2022238585A1 (en) 2022-11-17
AU2022272659A9 (en) 2023-11-30
ZA202311432B (en) 2025-04-30
US20250282831A1 (en) 2025-09-11
IL308407A (en) 2024-01-01
BR112023023794A2 (pt) 2024-03-12
EP4337250A1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
CN106573960B (zh) 用于针对乙型肝炎病毒感染的治疗性接种的合成长肽(slp)
CN114106164B (zh) 抗新型冠状病毒s蛋白的单克隆抗体及其应用
JP5042237B2 (ja) 血小板抗原特異抗体の結合を中和するペプチドアプタマー並びにそれを含む診断及び治療への応用
EP2970397A2 (en) Polypeptides for treating and/or limiting influenza infection
CN118984833A (zh) 表位的组合及其用途、疫苗构建体、诱导免疫反应的方法、表位的鉴定方法
US20260117202A1 (en) Mutant of rsv f protein
JP2026010683A (ja) 呼吸器合胞体ウイルスのｍＲＮＡワクチン及びその調製方法と使用
US20250282831A1 (en) Novel protein and nucleic acid sequences for covid-19 vaccines
Shah et al. Overexpression and characterization of the 100K protein of Fowl adenovirus-4 as an antiviral target
WO2022207860A2 (en) Combination therapy for covid-19 vaccination
WO2018175560A1 (en) Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
CN112262153B (zh) 高效的肝炎病毒的抗体诱导方法、抗体以及检测系统
US20170198014A1 (en) Polypeptides and their use for treating influenza
CN102432685A (zh) 检测重组小鼠碱性成纤维细胞生长因子的免疫胶乳微球及其制备方法和应用
CN116813767A (zh) 一种fgf21蛋白多克隆抗体制备方法
US6558675B1 (en) Mutant human hepatitis B viral strain and uses thereof
CN121494944B (zh) 一种马尔堡gp蛋白突变体、dna分子、重组载体及其应用
US20030003111A1 (en) Mutant human hepatitis B viral strain and uses thereof
CN114524870A (zh) 源自于ssx2抗原的短肽
CN110054675A (zh) 免疫原性多肽以及抗ttc36抗体cp4-3及应用
JPWO2002008416A1 (ja) 遺伝子免疫による抗体作製法
RU2562880C2 (ru) Синтетический пептид для получения моноспецифичных антител против изоформы 2 эукариотического фактора элонгации трансляции 1а
WO2023018805A1 (en) Methods and related aspects of detecting and purifying influenza neuraminidase
HK40069662B (en) Monoclonal antibody against novel coronavirus s protein and use thereof
CN119306808A (zh) 水痘-带状疱疹病毒gB蛋白突变体及其应用

Legal Events

Date Code Title Description
SREP Specification republished